TradeLink Capital LLC bought a new position in Maximus, Inc. (NYSE:MMS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 6,157 shares of the health services provider's stock, valued at approximately $460,000. Maximus makes up about 4.5% of TradeLink Capital LLC's holdings, making the stock its 7th biggest holding.
Other institutional investors have also recently made changes to their positions in the company. Larson Financial Group LLC raised its position in shares of Maximus by 36.1% during the 4th quarter. Larson Financial Group LLC now owns 2,144 shares of the health services provider's stock valued at $160,000 after buying an additional 569 shares in the last quarter. Edgestream Partners L.P. bought a new stake in shares of Maximus in the 4th quarter valued at approximately $568,000. Raymond James Financial Inc. purchased a new position in shares of Maximus in the 4th quarter worth approximately $1,169,000. Verdence Capital Advisors LLC bought a new position in Maximus during the 4th quarter valued at about $361,000. Finally, Aigen Investment Management LP bought a new stake in Maximus in the fourth quarter worth about $539,000. Hedge funds and other institutional investors own 97.21% of the company's stock.
Insider Buying and Selling at Maximus
In related news, CEO Bruce Caswell acquired 3,500 shares of the company's stock in a transaction that occurred on Tuesday, December 17th. The shares were bought at an average price of $70.64 per share, with a total value of $247,240.00. Following the completion of the transaction, the chief executive officer now directly owns 275,929 shares in the company, valued at $19,491,624.56. This trade represents a 1.28 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ilene R. Baylinson sold 14,500 shares of the business's stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $68.14, for a total transaction of $988,030.00. Following the completion of the transaction, the insider now owns 2,512 shares of the company's stock, valued at $171,167.68. This represents a 85.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.
Maximus Trading Up 0.4 %
NYSE:MMS traded up $0.27 during midday trading on Thursday, hitting $66.80. The stock had a trading volume of 399,254 shares, compared to its average volume of 480,905. The company has a quick ratio of 1.72, a current ratio of 1.72 and a debt-to-equity ratio of 0.82. The stock has a 50-day moving average of $72.40 and a 200 day moving average of $79.74. The company has a market capitalization of $3.78 billion, a price-to-earnings ratio of 14.37 and a beta of 0.71. Maximus, Inc. has a one year low of $63.77 and a one year high of $93.97.
Maximus (NYSE:MMS - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The health services provider reported $1.61 EPS for the quarter, beating the consensus estimate of $1.39 by $0.22. Maximus had a return on equity of 21.95% and a net margin of 5.28%. As a group, sell-side analysts forecast that Maximus, Inc. will post 6.15 EPS for the current year.
Maximus Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, February 28th. Investors of record on Saturday, February 15th were paid a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a yield of 1.80%. The ex-dividend date of this dividend was Friday, February 14th. Maximus's dividend payout ratio (DPR) is 25.81%.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on MMS shares. Raymond James raised Maximus from a "market perform" rating to an "outperform" rating and set a $90.00 price target for the company in a research note on Thursday, January 2nd. StockNews.com cut shares of Maximus from a "buy" rating to a "hold" rating in a report on Friday, February 14th.
Read Our Latest Analysis on MMS
About Maximus
(
Free Report)
Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.
Featured Stories

Before you consider Maximus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maximus wasn't on the list.
While Maximus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.